Julian Harrison
Stock Analyst at BTIG
(4.68)
# 176
Out of 5,149 analysts
97
Total ratings
61.8%
Success rate
25.42%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Julian Harrison
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TBPH Theravance Biopharma | Maintains: Buy | $40 → $21 | $13.96 | +50.43% | 5 | Mar 3, 2026 | |
| INVA Innoviva | Reiterates: Buy | $35 | $22.24 | +57.37% | 2 | Feb 26, 2026 | |
| AKBA Akebia Therapeutics | Maintains: Buy | $5 → $4 | $1.26 | +218.73% | 4 | Feb 25, 2026 | |
| ABVX ABIVAX Société Anonyme | Reiterates: Buy | $150 | $111.72 | +34.26% | 5 | Feb 25, 2026 | |
| MLTX MoonLake Immunotherapeutics | Maintains: Buy | $24 → $30 | $17.60 | +70.45% | 5 | Feb 23, 2026 | |
| SYRE Spyre Therapeutics | Reiterates: Buy | $70 | $40.41 | +73.25% | 5 | Feb 20, 2026 | |
| ARDX Ardelyx | Reiterates: Buy | $17 | $6.25 | +172.22% | 3 | Feb 20, 2026 | |
| NKTR Nektar Therapeutics | Maintains: Buy | $118 → $151 | $68.75 | +119.64% | 4 | Feb 10, 2026 | |
| MAZE Maze Therapeutics | Maintains: Buy | $37 → $46 | $44.20 | +4.07% | 4 | Jan 16, 2026 | |
| MREO Mereo BioPharma Group | Reiterates: Buy | $1 | $0.40 | +148.76% | 3 | Jan 16, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $49 | $31.26 | +56.75% | 6 | Jan 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $63 → $73 | $32.85 | +122.22% | 4 | Jan 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $5 | $3.07 | +63.13% | 5 | Jan 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $128 → $137 | $67.01 | +104.45% | 4 | Jan 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $32 → $38 | $15.53 | +144.69% | 2 | Nov 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $42 → $44 | $7.24 | +507.73% | 2 | Nov 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $10 | $2.52 | +297.61% | 2 | Nov 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $61 | $29.26 | +108.48% | 4 | Nov 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $82 | $92.68 | -11.52% | 3 | Oct 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $8 | $6.85 | +16.79% | 3 | Oct 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $55 → $15 | $3.85 | +289.61% | 1 | Oct 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $28 | $13.75 | +103.64% | 1 | Oct 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $40 | $17.45 | +129.23% | 2 | Sep 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $13.69 | - | 3 | Dec 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $53.99 | - | 2 | Dec 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $50 → $9 | $0.42 | +2,053.63% | 5 | Nov 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $8 | $3.03 | +164.46% | 4 | Nov 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $8 | $0.59 | +1,266.35% | 1 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Buy | $150 | $0.60 | +24,941.74% | 1 | Oct 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | n/a | $500.04 | - | 2 | Feb 11, 2022 |
Theravance Biopharma
Mar 3, 2026
Maintains: Buy
Price Target: $40 → $21
Current: $13.96
Upside: +50.43%
Innoviva
Feb 26, 2026
Reiterates: Buy
Price Target: $35
Current: $22.24
Upside: +57.37%
Akebia Therapeutics
Feb 25, 2026
Maintains: Buy
Price Target: $5 → $4
Current: $1.26
Upside: +218.73%
ABIVAX Société Anonyme
Feb 25, 2026
Reiterates: Buy
Price Target: $150
Current: $111.72
Upside: +34.26%
MoonLake Immunotherapeutics
Feb 23, 2026
Maintains: Buy
Price Target: $24 → $30
Current: $17.60
Upside: +70.45%
Spyre Therapeutics
Feb 20, 2026
Reiterates: Buy
Price Target: $70
Current: $40.41
Upside: +73.25%
Ardelyx
Feb 20, 2026
Reiterates: Buy
Price Target: $17
Current: $6.25
Upside: +172.22%
Nektar Therapeutics
Feb 10, 2026
Maintains: Buy
Price Target: $118 → $151
Current: $68.75
Upside: +119.64%
Maze Therapeutics
Jan 16, 2026
Maintains: Buy
Price Target: $37 → $46
Current: $44.20
Upside: +4.07%
Mereo BioPharma Group
Jan 16, 2026
Reiterates: Buy
Price Target: $1
Current: $0.40
Upside: +148.76%
Jan 13, 2026
Reiterates: Buy
Price Target: $49
Current: $31.26
Upside: +56.75%
Jan 12, 2026
Maintains: Buy
Price Target: $63 → $73
Current: $32.85
Upside: +122.22%
Jan 8, 2026
Reiterates: Buy
Price Target: $5
Current: $3.07
Upside: +63.13%
Jan 6, 2026
Maintains: Buy
Price Target: $128 → $137
Current: $67.01
Upside: +104.45%
Nov 24, 2025
Maintains: Buy
Price Target: $32 → $38
Current: $15.53
Upside: +144.69%
Nov 14, 2025
Maintains: Buy
Price Target: $42 → $44
Current: $7.24
Upside: +507.73%
Nov 13, 2025
Reiterates: Buy
Price Target: $10
Current: $2.52
Upside: +297.61%
Nov 4, 2025
Reiterates: Buy
Price Target: $61
Current: $29.26
Upside: +108.48%
Oct 28, 2025
Reiterates: Buy
Price Target: $82
Current: $92.68
Upside: -11.52%
Oct 16, 2025
Reiterates: Buy
Price Target: $8
Current: $6.85
Upside: +16.79%
Oct 13, 2025
Maintains: Buy
Price Target: $55 → $15
Current: $3.85
Upside: +289.61%
Oct 9, 2025
Initiates: Buy
Price Target: $28
Current: $13.75
Upside: +103.64%
Sep 29, 2025
Reiterates: Buy
Price Target: $40
Current: $17.45
Upside: +129.23%
Dec 12, 2024
Downgrades: Neutral
Price Target: n/a
Current: $13.69
Upside: -
Dec 2, 2024
Downgrades: Neutral
Price Target: n/a
Current: $53.99
Upside: -
Nov 29, 2024
Maintains: Buy
Price Target: $50 → $9
Current: $0.42
Upside: +2,053.63%
Nov 19, 2024
Upgrades: Buy
Price Target: $8
Current: $3.03
Upside: +164.46%
Nov 18, 2024
Initiates: Buy
Price Target: $8
Current: $0.59
Upside: +1,266.35%
Oct 11, 2023
Reinstates: Buy
Price Target: $150
Current: $0.60
Upside: +24,941.74%
Feb 11, 2022
Initiates: Neutral
Price Target: n/a
Current: $500.04
Upside: -